Citi lifts target on Acceleron Pharma

|About: Acceleron Pharma Inc. (XLRN)|By:, SA News Editor

Citi sees good things ahead for Acceleron Pharma (XLRN +2.4%) in 2014, as analyst Yaron Werber reiterates a Buy rating.

"In 2014 we expect multiple catalysts, extensive partnership with Celgene, and clinical data to continue to drive interest," Werber says, adding that Citi sees "data in both MDS and thalassemia [being] released at ASCO and EHA in June."

Price target hiked to $50 from $30.